A Year of Olaparib or a Window for Egg Retrieval: The Clock Runs on Both
OlympiA's protocol wants olaparib started within twelve weeks of finishing chemotherapy or surgery. She wants to attempt egg retrieval first. Both timelines are real and both are shrinking, and neither specialty controls the other's clock.
Beatriz N., a 34-year-old newlywed, was eight months into planning the family she and her husband had talked about since before the wedding when her BRCA1-positive, triple-negative diagnosis put that plan on an indefinite hold — and then, three weeks after finishing dose-dense chemotherapy, put a second, competing clock in front of her: OlympiA's own protocol calls for starting adjuvant olaparib within twelve weeks of completing chemotherapy or surgery, and a full course of fertility preservation, egg or embryo retrieval included, does not comfortably fit inside the nine weeks she has left in that window.
OlympiA randomized BRCA-mutant patients with high-risk early breast cancer to one year of adjuvant olaparib versus placebo, all started within that twelve-week post-treatment window, and found a substantial, durable improvement in both invasive disease-free and overall survival — a result specific to that patient population and, notably, to starting within that timeframe, since the trial itself never tested a meaningfully delayed start. Ovarian stimulation for egg or embryo retrieval typically runs two to three weeks from the start of injectable hormones to retrieval, which on its own could plausibly fit inside her remaining window — the real constraint is that PARP inhibitors are not given during active ovarian stimulation, since the DNA-repair pathway olaparib disrupts is also active in rapidly dividing oocytes, so any fertility-preservation cycle has to complete, egg-freeze and all, entirely before olaparib can start, not run alongside it. A short, deliberate delay to complete one stimulation cycle is a genuinely different proposal from an open-ended postponement, and OlympiA's twelve-week window itself has some real slack built in — it was chosen as a practical outer bound for recovery from surgery and chemotherapy, not derived from a mechanistic finding that outcomes collapse at week thirteen.
Oncofertility consultation
OlympiA's survival benefit is one of the more substantial results in this space, and the trial's own design started every patient within twelve weeks — I want to protect that window and start olaparib now rather than risk any delay in a curative-intent adjuvant setting.
I understand the instinct to start immediately, and I want to be clear I'm not asking to set fertility preservation against her survival — a single stimulation cycle, done efficiently, adds roughly two to three weeks, which still lands inside week eleven or twelve of her existing window, not past it.
That's a fair distinction from an open-ended delay, and it changes my read of this — a two-to-three-week cycle that stays inside the trial's own window isn't the same request as postponing olaparib indefinitely, which is what I was originally reacting against.
The mechanistic point worth naming plainly for her: olaparib and active ovarian stimulation genuinely can't run together, since the same homologous-recombination pathway the drug disrupts in her tumor is also active in a stimulated ovary — this isn't a scheduling inconvenience, it's a real pharmacologic incompatibility, which is why the sequence has to be egg retrieval first, olaparib second, not overlapping.
Given that, a single, tightly-timed stimulation cycle that completes by week eleven protects both the survival benefit OlympiA demonstrated and her stated wish to preserve fertility before a year of a drug whose own effect on future fertility isn't fully characterized.
Agreed: one compressed ovarian stimulation and egg-retrieval cycle beginning immediately, timed to complete by week eleven, with olaparib starting the following week — inside OlympiA's twelve-week window, not past it.